What question did this study set out to answer?

To evaluate the effectiveness and safety of monoclonal antibodies in treating relapsing remitting multiple sclerosis.

April 24, 2026Journal of Neurology1 citationsOpen Access

Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review

AAAna Avedillo-SalasUniversidad de Zaragoza LMLaura Baeza MartínezUniversidad de Zaragoza AFAna Fanlo-VillacampaUniversidad de Zaragoza

Key Points

To evaluate the effectiveness and safety of monoclonal antibodies in treating relapsing remitting multiple sclerosis.
Conducted a systematic review of existing literature on monoclonal antibody treatments.
Assessed both clinical and radiological outcomes compared to conventional therapies.
Considered the risks and benefits for high-risk patients.
Monoclonal antibodies showed superior clinical benefits over conventional treatments.
Radiological improvements were also noted with monoclonal antibody use.
Individualized treatment plans are necessary due to potential adverse effects, particularly in high-risk groups.

Abstract

Monoclonal antibodies are an effective option in RRMS, with clinical and radiological benefits superior to those of conventional treatments. Their use requires individualized assessment and close follow-up due to the risk of adverse effects, especially in high-risk patients.

问 AI

Bookmark

View Full Paper